Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
British journal of dermatology. - 182, 6 (2020) , 1437-1448, ISSN: 1365-2133
- Schlagwort
-
Epidermolysis bullosa
Wachstum
Anämie
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2020
- Urheber
- DOI
-
10.1111/bjd.18475
- URN
-
urn:nbn:de:bsz:25-freidok-1661446
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Reimer-Taschenbrecker, Antonia
- Hess, Moritz
- Schwieger-Briel, Agnes
- Kiritsi, Dimitra
- Schauer, Franziska
- Schumann, Hauke
- Bruckner-Tuderman, Leena
- Has, Cristina
- Universität
Entstanden
- 2020
Ähnliche Objekte (12)
Dupilumab verbessert Juckreiz und Blasenbildung bei verschiedenen Subtypen der Epidermolysis bullosa : = Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
Betulin-based oleogel to improve wound healing in dystrophic epidermolysis bullosa: a prospective controlled proof-of-concept study
Dupilumab zur Behandlung der Epidermolysis bullosa acquisita
Treatment of Epidermolysis bullosa acquisita with dupilumab
Recent advances in understanding and managing epidermolysis bullosa
Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers
Molecular therapeutics in development for Epidermolysis bullosa: update 2020
Treatment of epidermolysis bullosa and future directions: a review
Strategy for the optimization of read-through therapy for junctional epidermolysis bullosa with COL17A1 nonsense mutation
Case report: Diagnostic and therapeutic challenges in severe mechanobullous epidermolysis bullosa acquisita
Molecular and genetic mechanisms in junctional epidermolysis bullosa
Dupilumab verbessert Juckreiz und Blasenbildung bei verschiedenen Subtypen der Epidermolysis bullosa : = Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
Betulin-based oleogel to improve wound healing in dystrophic epidermolysis bullosa: a prospective controlled proof-of-concept study
Dupilumab zur Behandlung der Epidermolysis bullosa acquisita
Treatment of Epidermolysis bullosa acquisita with dupilumab
Recent advances in understanding and managing epidermolysis bullosa
Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers
Molecular therapeutics in development for Epidermolysis bullosa: update 2020
Treatment of epidermolysis bullosa and future directions: a review
Strategy for the optimization of read-through therapy for junctional epidermolysis bullosa with COL17A1 nonsense mutation
Case report: Diagnostic and therapeutic challenges in severe mechanobullous epidermolysis bullosa acquisita
Molecular and genetic mechanisms in junctional epidermolysis bullosa
Dupilumab verbessert Juckreiz und Blasenbildung bei verschiedenen Subtypen der Epidermolysis bullosa : = Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
Betulin-based oleogel to improve wound healing in dystrophic epidermolysis bullosa: a prospective controlled proof-of-concept study
Dupilumab zur Behandlung der Epidermolysis bullosa acquisita
Treatment of Epidermolysis bullosa acquisita with dupilumab
Recent advances in understanding and managing epidermolysis bullosa
Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers
Molecular therapeutics in development for Epidermolysis bullosa: update 2020
Treatment of epidermolysis bullosa and future directions: a review
Strategy for the optimization of read-through therapy for junctional epidermolysis bullosa with COL17A1 nonsense mutation
Case report: Diagnostic and therapeutic challenges in severe mechanobullous epidermolysis bullosa acquisita